Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan, Docetaxel, and Celecoxib in Advanced NSCLC
NCT00073866Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Jun 2003
- Primary completion
- Dec 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of celecoxib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Northwestern University. Primary endpoints: Recommended Phase II Dose and Dose-Limiting Toxicity. Started Jun 2003; status: completed.
02
Drugs
celecoxib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00073866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073866.